Vanguard Personalized Indexing Management LLC Has $1.09 Million Position in Genmab A/S Sponsored ADR $GMAB

Key Points

• Vanguard Personalized Indexing Management LLC increased its holdings in Genmab A/S by 24.7%, owning 52,684 shares worth approximately $1.09 million.
• Genmab A/S reported $0.54 earnings per share for the latest quarter, exceeding estimates, with revenues of $925 million compared to a consensus of $5.77 billion.
• Wall Street analysts have mixed ratings on Genmab A/S, with an average rating of "Moderate Buy" and a consensus price target of $40.80.

Vanguard Personalized Indexing Management LLC raised its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 24.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 52,684 shares of the company's stock after buying an additional 10,426 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Genmab A/S were worth $1,088,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Blue Trust Inc. boosted its holdings in Genmab A/S by 169.9% in the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock valued at $145,000 after purchasing an additional 4,666 shares during the period. Oppenheimer Asset Management Inc. raised its position in shares of Genmab A/S by 20.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company's stock valued at $4,885,000 after buying an additional 42,361 shares during the last quarter. DAVENPORT & Co LLC lifted its stake in shares of Genmab A/S by 21.1% in the first quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company's stock valued at $620,000 after buying an additional 5,529 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Genmab A/S by 1.7% in the first quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company's stock valued at $14,417,000 after buying an additional 12,545 shares during the period. Finally, Callan Capital LLC acquired a new stake in Genmab A/S during the first quarter worth about $281,000. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $33.17 on Friday. The company's fifty day moving average is $27.95 and its 200-day moving average is $23.36. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $33.65. The company has a market capitalization of $21.30 billion, a PE ratio of 16.67, a P/E/G ratio of 1.85 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. On average, analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on GMAB shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Genmab A/S in a report on Wednesday, October 8th. Wall Street Zen cut Genmab A/S from a "strong-buy" rating to a "buy" rating in a research report on Saturday. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Genmab A/S in a research note on Wednesday. Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, Zacks Research raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.